IS5696A - Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra - Google Patents

Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra

Info

Publication number
IS5696A
IS5696A IS5696A IS5696A IS5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A
Authority
IS
Iceland
Prior art keywords
derivatives
antibodies against
therapeutic use
therapeutic
antibodies
Prior art date
Application number
IS5696A
Other languages
English (en)
Inventor
Marcel Paul Bonnefoy Jean-Yves
James Crowe Scott
Henry Ellis Jonathan
Timothy Rapson Nicholas
Shearin Jean
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5696A publication Critical patent/IS5696A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS5696A 1998-05-09 2000-10-31 Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra IS5696A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
IS5696A true IS5696A (is) 2000-10-31

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5696A IS5696A (is) 1998-05-09 2000-10-31 Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra

Country Status (25)

Country Link
US (1) US7008623B1 (is)
EP (1) EP1076701A1 (is)
JP (1) JP2002514421A (is)
KR (1) KR20010043470A (is)
CN (1) CN1308676A (is)
AP (1) AP1547A (is)
AU (1) AU763491B2 (is)
BR (1) BR9910327A (is)
CA (1) CA2328606A1 (is)
EA (1) EA200001041A1 (is)
EE (1) EE200000658A (is)
GB (1) GB9809839D0 (is)
HR (1) HRP20000762A2 (is)
HU (1) HUP0102005A3 (is)
ID (1) ID28088A (is)
IL (1) IL139384A0 (is)
IS (1) IS5696A (is)
NO (1) NO20005632L (is)
NZ (1) NZ507879A (is)
PL (1) PL344019A1 (is)
SK (1) SK16762000A3 (is)
TR (1) TR200003281T2 (is)
WO (1) WO1999058679A1 (is)
YU (1) YU69000A (is)
ZA (1) ZA200006312B (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EE200300179A (et) 2000-10-13 2003-08-15 Biogen, Inc. Humaniseeritud LT-ß-R-i vastased antikehad
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
EP2135619A1 (en) * 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
WO2006039470A2 (en) * 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US20090155255A1 (en) * 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
EP2641919A3 (en) 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
AR072359A1 (es) 2008-05-06 2010-08-25 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2401296A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120058116A1 (en) 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
WO2012069433A2 (en) 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
JP2014501725A (ja) 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
SG194176A1 (en) 2011-05-27 2013-12-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
HRP20201113T1 (hr) 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Vežući proteini protiv lag-3
CA2917661C (en) * 2013-07-10 2023-09-12 Onconox Aps Antibodies to .beta.2-glycoprotein i and therapeutic uses thereof
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RU2021133819A (ru) 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
US10479827B2 (en) * 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
JP7355742B2 (ja) 2018-01-18 2023-10-03 フレッド ハッチンソン キャンサー センター 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
MA56397A (fr) 2019-06-26 2022-05-04 Glaxosmithkline Ip Dev Ltd Protéines de liaison à l'il1rap
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
BR9206313A (pt) * 1991-07-25 1995-04-11 Idec Pharma Corp Anticorpos recombinantes para terapia humana.
US6627195B1 (en) * 1994-10-25 2003-09-30 Smithkline Beecham Corporation Binding agents to CD23
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
JP2002514421A (ja) 2002-05-21
NZ507879A (en) 2004-02-27
CA2328606A1 (en) 1999-11-18
US7008623B1 (en) 2006-03-07
HRP20000762A2 (en) 2001-06-30
SK16762000A3 (sk) 2001-07-10
WO1999058679A1 (en) 1999-11-18
BR9910327A (pt) 2001-01-30
GB9809839D0 (en) 1998-07-08
HUP0102005A2 (hu) 2001-10-28
AU3836799A (en) 1999-11-29
EE200000658A (et) 2002-04-15
PL344019A1 (en) 2001-09-24
KR20010043470A (ko) 2001-05-25
AP2000001983A0 (en) 2000-12-31
HUP0102005A3 (en) 2003-10-28
CN1308676A (zh) 2001-08-15
ID28088A (id) 2001-05-03
TR200003281T2 (tr) 2001-03-21
EP1076701A1 (en) 2001-02-21
IL139384A0 (en) 2001-11-25
ZA200006312B (en) 2003-02-26
YU69000A (sh) 2003-08-29
AP1547A (en) 2006-01-13
NO20005632D0 (no) 2000-11-08
NO20005632L (no) 2001-01-08
EA200001041A1 (ru) 2001-06-25
AU763491B2 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
IS5696A (is) Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
IS5760A (is) Meðferðarlegar bíarýl afleiður
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
DK1019358T3 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
TR199800117A3 (tr) Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
NO20013237L (no) 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO986174L (no) Triazinderivater og anvendelse derav
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse
NO996156L (no) Substituerte cykloheptener, deres fremstilling og anvendelse